AGY Therapeutics Inc., of South San Francisco, was issued U.S. patent No. 6,455,026 titled "Use of Protein Tyrosine Phosphatase Zeta as a Biomolecular Target in the Treatment and Visualization of Brain Tumors."

Alchemia Pty. Ltd., of Brisbane, Australia, was awarded U.S. Patent No. 6,462,183 titled "Protected Aminosugars," covering aspects of the company's technology to discover and produce carbohydrate-based therapeutics.

Cubist Pharmaceuticals Inc., of Lexington, Mass., was issued U.S. Patent No. 6,468,967 titled "Methods for Administration of Antibiotics," providing until at least the year 2019 market exclusivity in the U.S. for once-daily administration of its investigational antibiotic Cidecin (daptomycin for injection), should it receive approval.

Harvard Bioscience Inc., of Holliston, Mass., said its wholly owned subsidiary, Genomic Solutions Inc., was awarded a second patent covering its genomics technology. U.S. Patent No. 6,432,696 titled "Thermal and Fluidic Cycling Device for Nucleic Acid Hybridization" describes a system that automates the processing of DNA and protein microarrays.

MethylGene Inc., of Montreal, received U.S. Patent No. 6,472,406 titled "Novel Sulfonamidomethylphosphonate Inhibitors of B-Lactamase." It covers novel beta-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic beta-lactamase inhibitors presently available that do not contain a beta-lactam pharmacophore, and pharmaceutical compositions and methods for inhibiting bacterial growth.

Pharmacor Inc., of Montreal, was issued U.S. patent application No. 10/143,095, relating to its antiretroviral program. The small-molecule compounds described in the patent, titled "Urea derivatives as HIV aspartyl protease inhibitors," are next-generation anti-HIV lead molecules that demonstrate inhibitory activity both on laboratory strains and on multidrug-resistant strains of the virus.

Pozen Inc., of Chapel Hill, N.C., received U.S. Patent No. 6,479,551, expanding protection for MT 100, its oral product candidate designed for first-line migraine therapy, through claims relating to additional pharmaceutical compositions and treatment methods.

Provectus Pharmaceuticals Inc., of Knoxville, Tenn., received both U.S. Patent No. 6,468,777 and U.S. Patent No. 6,451,597, covering methods to genetically modify cells on a permanent basis. Provectus said the genetic modification improves the amount of vaccine produced and also the vaccine's performance.

TopoTarget Prolifix A/S, of Copenhagen, Denmark, was granted U.S. Patent No. 6,368,809 B1 relating to a mechanism that modulates cellular levels of E2F, a protein that plays a role in controlling both cell proliferation and death.